Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“New in American Journal of Hematology – The WAVe Study
In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing.”
Title: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Read full article here.
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice
-
Jul 2, 2026, 21:49Lee Peter Bee: The Plastic in Your Blood Is Sabotaging Your Stem Cells
-
Jul 2, 2026, 21:49Atef Ahmed: The Lethal Triad and Damage Control Philosophy
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT